Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	There are no antibodies.	n/a

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	There are no cell materials.	n/a
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	There are no cell materials.	n/a

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	There are no experimental animals.	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	There are no experimental animals.	n/a
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID	There are no experimental animals.	n/a

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	There are no plants nor microbes.	n/a
Microbes: provide species and strain, unique accession number if available, and source	There are no plants nor microbes.	n/a

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	There are no human research participants.	n/a
Provide statement confirming informed consent obtained from study participants.	There are no human research participants.	n/a
Report on age and sex for all study participants.	There are no human research participants.	n/a

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	It is not clinical trial.	n/a

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	It is not laboratory study.	n/a

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination	It is not experimental study.	n/a
Randomisation	It is not experimental study.	n/a
Blinding	It is not experimental study.	n/a
Inclusion/exclusion criteria	It is not experimental study.	n/a

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	It is not laboratory study.	n/a
Define whether data describe technical or biological replicates	It is not laboratory study.	n/a

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	There are no human participants.	n/a
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	There are no experimental animals.	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	There are no specimen or field samples.	n/a

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	It is not dual use research.	n/a

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	There are no samples.	n/a

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Yes Statistical analysis was included in the last paragraph of "Method" Section.	n/a

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	There are no newly created datasets.	n/a
If data are publicly available, provide accession number in repository or DOI or URL.	Yes https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129492 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15471 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16515 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28735	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	They are not reused.	n/a

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	There is no code.	n/a
If code is publicly available, provide accession number in repository, or DOI or URL.	There is no code.	n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/gs-20-828